Battle of the Midway in the Range

Although the stock trades too thinly in terms of volume for my taste, GLPG was a new issue biotech we looked at in this blog post not long ago as a long setup. Indeed, several Members inside Market Chess Subscription Services pounced on the play, and are benefitting from the sizable move higher today. 

Going forward, aa long as GLPG holds over $59 I am constructive on the name. 

In addition, despite a flat Dow and a rangebound S&P, many individual biotechs are zooming higher today. I am refining a list for Members as we speak, and will cover it in my usual Midday Video.